Reasonable approaches include: Stabilization approach: Wait until Ozempic dose is titrated to maintenance level and side effects have stabilized, typically 4-8 weeks
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
For a systemic, synergistic effect with Methylene Blue, a research protocol would likely utilize an injectable form for broader distribution
Only a few studies matched cases and controls for age [60, 68, 74, 75, 83] and/or gender [48, 60, 75, 83, 89] despite the acknowledged difference in prevalence between genders [99], and most did not state the source of controls [48, 59, 60, 63, 6870, 73, 74, 76, 78, 81, 84]
Take the tablet as prescribed by your doctor for optimal results
